Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schwoerer

Showing results (161-170 of 265) with videos related to

Pageof 27
Sort By:
Nature Communications|May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Biorxiv : the Preprint Server for Biology|July 1, 2024
Liver-specific Mettl14 deletion induces nuclear heterotypia and dysregulates RNA export machineryKeith A Berggren, Saloni Sinha, Aaron E Lin, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of ExpertsChristoph Thomssen, Diana Lüftner, Michael Untch, et al.
NPJ Vaccines|June 11, 2025
Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicityLiudmila Kulakova, Kiki H Li, Austin W T Chiang, et al.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Nature Communications|March 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trialSonja Loges, Michael Heuser, Jörg Chromik, et al.
Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Nature Medicine|March 23, 2010
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillationVolker Rudolph, René P Andrié, Tanja K Rudolph, et al.
The Journal of Clinical Investigation|February 26, 2013
Parthenogenetic stem cells for tissue-engineered heart repairMichael Didié, Peter Christalla, Michael Rubart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Pageof 27

Showing results (161-170 of 265) with videos related to

Sort By:
Pageof 27
Nature Communications|May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutationSibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Biorxiv : the Preprint Server for Biology|July 1, 2024
Liver-specific Mettl14 deletion induces nuclear heterotypia and dysregulates RNA export machineryKeith A Berggren, Saloni Sinha, Aaron E Lin, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of ExpertsChristoph Thomssen, Diana Lüftner, Michael Untch, et al.
NPJ Vaccines|June 11, 2025
Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicityLiudmila Kulakova, Kiki H Li, Austin W T Chiang, et al.
Leukemia|June 24, 2017
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemiaV I Gaidzik, D Weber, P Paschka, et al.
Nature Communications|March 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trialSonja Loges, Michael Heuser, Jörg Chromik, et al.
Blood|September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study GroupFrank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Nature Medicine|March 23, 2010
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillationVolker Rudolph, René P Andrié, Tanja K Rudolph, et al.
The Journal of Clinical Investigation|February 26, 2013
Parthenogenetic stem cells for tissue-engineered heart repairMichael Didié, Peter Christalla, Michael Rubart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2019
Gemtuzumab Ozogamicin in <i>NPM1</i>-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III StudyRichard F Schlenk, Peter Paschka, Julia Krzykalla, et al.
Pageof 27